MRD & MCED Adela is accelerating cancer diagnosis and management with blood-based minimal residual disease and multi-cancer early detection tests, presenting a compelling opportunity to cross-sell to oncology clinics, hospitals, and blood testing networks seeking non-tissue dependent diagnostics.

Tissue-Free Advantage The tissue-free MRD test enables universal accessibility for cancer monitoring, suggesting sales potential to community hospitals and regional centers that lack access to tumor tissue samples for traditional MRD approaches.

Expanding Indications Recent and upcoming launches for head and neck cancer MRD and broader MCED applications indicate growth momentum and upsell potential to centers treating multiple cancer types, including immunotherapy patients.

Clinical Validation Two clinically validated applications and recent ASCO presentations provide strong evidence to support payer conversations, adoption by value-based care programs, and adoption by academic and community oncology practices.

Strategic Partnerships Recent collaboration with Dendi for commercialization and strong investor recognition (OrbiMed backing) signal a scalable go-to-market cadence, offering opportunities to co-sell with partners and leverage existing distribution channels.